A citation-based method for searching scientific literature

Narikazu Boku. Gastric Cancer 2014
Times Cited: 191







List of co-cited articles
428 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
46

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
28

Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
M Hofmann, O Stoss, D Shi, R Büttner, M van de Vijver, W Kim, A Ochiai, J Rüschoff, T Henkel. Histopathology 2008
805
13

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, Jian M Xu, Keun-Wook Lee, Shun-Chang Jiao, Jorge León Chong, Roberto I López-Sanchez, Timothy Price, Oleg Gladkov,[...]. Gastric Cancer 2015
242
12


HER2 testing in gastric cancer: An update.
Lucas Faria Abrahao-Machado, Cristovam Scapulatempo-Neto. World J Gastroenterol 2016
109
10

HER2-targeted therapies - a role beyond breast cancer.
Do-Youn Oh, Yung-Jue Bang. Nat Rev Clin Oncol 2020
215
10

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray. Int J Cancer 2015
9


HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.
Josef Rüschoff, Manfred Dietel, Gustavo Baretton, Susanne Arbogast, Axel Walch, Geneviéve Monges, Marie-Pierre Chenard, Frédérique Penault-Llorca, Iris Nagelmeier, Werner Schlake,[...]. Virchows Arch 2010
340
8

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
E C Smyth, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold. Ann Oncol 2016
756
8

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
Y Y Janjigian, D Werner, C Pauligk, K Steinmetz, D P Kelsen, E Jäger, H M Altmannsberger, E Robinson, L J Tafe, L H Tang,[...]. Ann Oncol 2012
220
8

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Funda Meric-Bernstam, Amber M Johnson, Ecaterina E Ileana Dumbrava, Kanwal Raghav, Kavitha Balaji, Michelle Bhatt, Rashmi K Murthy, Jordi Rodon, Sarina A Piha-Paul. Clin Cancer Res 2019
109
8


Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. J Clin Oncol 2013
7

HER2 testing in gastric cancer: a practical approach.
Josef Rüschoff, Wedad Hanna, Michael Bilous, Manfred Hofmann, Robert Y Osamura, Frédérique Penault-Llorca, Marc van de Vijver, Giuseppe Viale. Mod Pathol 2012
357
7

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I Jalal, Manish A Shah, Jean-Phillipe Metges,[...]. JAMA Oncol 2018
834
7

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, Hyun C Chung, Jianming M Xu, Joon O Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M Hoff, Alberto Sobrero,[...]. J Clin Oncol 2016
341
7

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
7

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara,[...]. Lancet Oncol 2017
227
7

Gastric cancer.
Eric Van Cutsem, Xavier Sagaert, Baki Topal, Karin Haustermans, Hans Prenen. Lancet 2016
7

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim,[...]. Lancet Oncol 2014
7

Cancer statistics in China, 2015.
Wanqing Chen, Rongshou Zheng, Peter D Baade, Siwei Zhang, Hongmei Zeng, Freddie Bray, Ahmedin Jemal, Xue Qin Yu, Jie He. CA Cancer J Clin 2016
6

Global cancer statistics, 2012.
Lindsey A Torre, Freddie Bray, Rebecca L Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal. CA Cancer J Clin 2015
6

HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
Federica Grillo, Matteo Fassan, Francesca Sarocchi, Roberto Fiocca, Luca Mastracci. World J Gastroenterol 2016
58
10


Perspectives of HER2-targeting in gastric and esophageal cancer.
James N Gerson, Sam Skariah, Crystal S Denlinger, Igor Astsaturov. Expert Opin Investig Drugs 2017
45
13

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
6

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim,[...]. Lancet Oncol 2018
182
6

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee,[...]. N Engl J Med 2020
240
6

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun C Chung,[...]. Lancet 2018
599
5

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
Angela N Bartley, Mary Kay Washington, Carol Colasacco, Christina B Ventura, Nofisat Ismaila, Al B Benson, Alfredo Carrato, Margaret L Gulley, Dhanpat Jain, Sanjay Kakar,[...]. J Clin Oncol 2017
158
5

Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
Hee Eun Lee, Kyoung Un Park, Seol Bong Yoo, Soo Kyung Nam, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee. Eur J Cancer 2013
110
5

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Taroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, Guo-Ping Sun, Toshihiko Doi, Jian-Ming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jin-Wan Wang,[...]. J Clin Oncol 2014
390
5


Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients.
A Marcell Szász, András Lánczky, Ádám Nagy, Susann Förster, Kim Hark, Jeffrey E Green, Alex Boussioutas, Rita Busuttil, András Szabó, Balázs Győrffy. Oncotarget 2016
624
5


Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
4

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
4

Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.
Parisa Karimi, Farhad Islami, Sharmila Anandasabapathy, Neal D Freedman, Farin Kamangar. Cancer Epidemiol Biomarkers Prev 2014
880
4

Treatment of gastric cancer.
Michele Orditura, Gennaro Galizia, Vincenzo Sforza, Valentina Gambardella, Alessio Fabozzi, Maria Maddalena Laterza, Francesca Andreozzi, Jole Ventriglia, Beatrice Savastano, Andrea Mabilia,[...]. World J Gastroenterol 2014
386
4

HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.
Heike Grabsch, Shivan Sivakumar, Sally Gray, Helmut E Gabbert, Wolfram Müller. Cell Oncol 2010
209
4

Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study.
Nirmala Pathmanathan, Jing-Shu Geng, Wencai Li, Xiu Nie, Januario Veloso, John Wang, Julie Hill, Philip Mccloud, Michael Bilous. Asia Pac J Clin Oncol 2017
7
57

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
J S Macdonald, S R Smalley, J Benedetti, S A Hundahl, N C Estes, G N Stemmermann, D G Haller, J A Ajani, L L Gunderson, J M Jessup,[...]. N Engl J Med 2001
4

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M Hyman, Sarina A Piha-Paul, Helen Won, Jordi Rodon, Cristina Saura, Geoffrey I Shapiro, Dejan Juric, David I Quinn, Victor Moreno, Bernard Doger,[...]. Nature 2018
364
4

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
Hyun-Soo Cho, Karen Mason, Kasra X Ramyar, Ann Marie Stanley, Sandra B Gabelli, Dan W Denney, Daniel J Leahy. Nature 2003
4

The ERBB network: at last, cancer therapy meets systems biology.
Yosef Yarden, Gur Pines. Nat Rev Cancer 2012
539
4

The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature.
Yu-Ying Lei, Jin-Yu Huang, Qiong-Rui Zhao, Nan Jiang, Hui-Mian Xu, Zhen-Ning Wang, Hai-Qing Li, Shi-Bo Zhang, Zhe Sun. World J Surg Oncol 2017
58
6

Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
De-Shen Wang, Ze-Xian Liu, Yun-Xin Lu, Hua Bao, Xue Wu, Zhao-Lei Zeng, Zekun Liu, Qi Zhao, Cai-Yun He, Jia-Huan Lu,[...]. Gut 2019
64
6

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.
Hong-Bo Wang, Xiao-Feng Liao, Jian Zhang. Medicine (Baltimore) 2017
27
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.